Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Sinovac Biotech Ltd. (SVA) Report Updated: Oct 15, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Sinovac Biotech Ltd. (SVA)

Rating: Buy Volatility: Conservative
Total Grade: B Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

Sinovac Biotech Ltd.© quotemedia

Company Profile

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, influenza viruses, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; Split viron pandemic influenza vaccine; and RabEnd, an animal rabies vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. In addition, it has completed pre-clinical studies for varicella, sabin inactivated polio, and hepatitis A and B vaccines; and focuses on commencing clinical trials for pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and rubella vaccine. The company has a collaboration agreement with Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.